q2 adjusted non-gaap earnings per share $2.46.
q2 revenue $7.2 billion versus refinitiv ibes estimate of $6.72 billion.
for q3 2021, anticipates that non-gaap core revenue growth will be in mid- to high-teens percent range.
for full year 2021, now anticipates that non-gaap core revenue growth rate including cytiva will be about 20%.
